Английская Википедия:AB-PINACA
Шаблон:Short description Шаблон:Drugbox
AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012.[1]
It was originally developed by Pfizer in 2009 as an analgesic medication.[2][3]
AB-PINACA acts as a potent agonist for the CB1 receptor (Ki = 2.87 nM, EC50 = 1.2 nM) and CB2 receptor (Ki = 0.88 nM, EC50 = 2.5 nM) and fully substitutes for Δ9-THC in rat discrimination studies, while being 1.5x more potent.[4][5]
There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.[6][7]
Legal status
Germany
AB-PINACA is an Anlage II controlled substance in Germany as of November 2014.[8]
Singapore
It is listed in the Fifth Schedule of the Misuse of Drugs Act and so is illegal in Singapore, as of May 2015.[9]
United States
It is a Schedule I controlled substance in the United States.[10]
China
It is a controlled substance in China as of October 2015.[11]
France
It is a controlled substance in France as of March 2017.[12]
See also
- 5F-AB-PINACA
- 5F-ADB
- 5F-AMB
- 5F-APINACA
- 5F-CUMYL-PINACA
- AB-CHFUPYCA
- AB-FUBINACA
- AB-PICA
- ADB-CHMINACA
- ADB-FUBINACA
- ADB-PINACA
- ADBICA
- APICA
- APINACA
- MDMB-CHMICA
- PX-3
References